MCL Featured Stories
Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.
Learn how GFAP testing is emerging as a biomarker to support diagnosis, monitoring, and prognosis in neurological diseases.
Join us at the 2026 Mayo Clinic Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders, where innovation, collaboration, and expertise come together to advance the field of hematology.
Tick-borne diseases are increasing across the United States as tick populations and their geographic range continue to expand. This presentation reviews current trends in tick-borne diseases, highlights major tick vectors and associated pathogens, discusses prevention strategies, and explores the laboratory's role in supporting accurate diagnosis and patient care.
Discover how Mayo Clinic’s nationally recognized Muscle Pathology Laboratory provides unparalleled diagnostic accuracy for rare muscle diseases through decades of experience, specialized testing, and integrated clinical-pathological evaluation.
Supported by Mayo Clinic’s holistic, precision medicine approach, which included advanced genetic insights, access to an emerging therapy, and tailored treatment monitoring, Giana Urse gained the confidence and clarity she needed to pursue her dream of becoming a dog trainer.
Autoimmune encephalitis (AE) is a rare but serious condition, and accurate diagnosis is critical. Misdiagnosis can lead to unnecessary treatments, delayed care, and preventable complications.
This presentation explores the current rare disease and genomic healthcare landscape in Barbados
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent industry news and how clinical diagnostics are powering more personalized care.
Our annual outreach conference will take place Sept. 23–24, 2026, in Rochester, Minnesota. This year’s event, Leveraging the Laboratory: Bold Thinking. Big Impact., focuses on how innovative approaches and strategic decision-making can drive meaningful results for health system laboratory outreach programs.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.
We are excited to announce that registration is now open for the 2026 Mayo Clinic Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders.
Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.